414 related articles for article (PubMed ID: 32757967)
1. Inflammasomes: a preclinical assessment of targeting in atherosclerosis.
Stitham J; Rodriguez-Velez A; Zhang X; Jeong SJ; Razani B
Expert Opin Ther Targets; 2020 Sep; 24(9):825-844. PubMed ID: 32757967
[TBL] [Abstract][Full Text] [Related]
2. BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in
Yalcinkaya M; Liu W; Thomas LA; Olszewska M; Xiao T; Abramowicz S; Papapetrou EP; Westerterp M; Wang N; Tabas I; Tall AR
Circulation; 2023 Nov; 148(22):1764-1777. PubMed ID: 37781816
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.
Westerterp M; Fotakis P; Ouimet M; Bochem AE; Zhang H; Molusky MM; Wang W; Abramowicz S; la Bastide-van Gemert S; Wang N; Welch CL; Reilly MP; Stroes ES; Moore KJ; Tall AR
Circulation; 2018 Aug; 138(9):898-912. PubMed ID: 29588315
[TBL] [Abstract][Full Text] [Related]
4. Deficient Chaperone-Mediated Autophagy Promotes Inflammation and Atherosclerosis.
Qiao L; Ma J; Zhang Z; Sui W; Zhai C; Xu D; Wang Z; Lu H; Zhang M; Zhang C; Chen W; Zhang Y
Circ Res; 2021 Dec; 129(12):1141-1157. PubMed ID: 34704457
[TBL] [Abstract][Full Text] [Related]
5. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
Satish M; Agrawal DK
Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
[TBL] [Abstract][Full Text] [Related]
6. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Grebe A; Hoss F; Latz E
Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
[TBL] [Abstract][Full Text] [Related]
8. Activation of NLRP3 inflammasomes contributes to hyperhomocysteinemia-aggravated inflammation and atherosclerosis in apoE-deficient mice.
Wang R; Wang Y; Mu N; Lou X; Li W; Chen Y; Fan D; Tan H
Lab Invest; 2017 Aug; 97(8):922-934. PubMed ID: 28394319
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights of cigarette smoke condensate-activated NLRP3 inflammasome in THP-1 cells in a stage-specific atherogenesis.
Mehta S; Dhawan V
Int Immunopharmacol; 2020 Nov; 88():107013. PubMed ID: 33182063
[TBL] [Abstract][Full Text] [Related]
11. A Spotlight on the Underlying Activation Mechanisms of the NLRP3 Inflammasome and its Role in Atherosclerosis: A Review.
Liaqat A; Asad M; Shoukat F; Khan AU
Inflammation; 2020 Dec; 43(6):2011-2020. PubMed ID: 32656610
[TBL] [Abstract][Full Text] [Related]
12. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis.
Chen S; Wang Y; Pan Y; Liu Y; Zheng S; Ding K; Mu K; Yuan Y; Li Z; Song H; Jin Y; Fu J
J Am Heart Assoc; 2020 Jun; 9(12):e015513. PubMed ID: 32476536
[TBL] [Abstract][Full Text] [Related]
13. p38δ MAPK: A Novel Regulator of NLRP3 Inflammasome Activation With Increased Expression in Coronary Atherogenesis.
Rajamäki K; Mäyränpää MI; Risco A; Tuimala J; Nurmi K; Cuenda A; Eklund KK; Öörni K; Kovanen PT
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1937-46. PubMed ID: 27417584
[TBL] [Abstract][Full Text] [Related]
14. Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs.
Li Y; Xu S; Jiang B; Cohen RA; Zang M
PLoS One; 2013; 8(6):e67532. PubMed ID: 23825667
[TBL] [Abstract][Full Text] [Related]
15. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis.
Hoseini Z; Sepahvand F; Rashidi B; Sahebkar A; Masoudifar A; Mirzaei H
J Cell Physiol; 2018 Mar; 233(3):2116-2132. PubMed ID: 28345767
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.
An N; Gao Y; Si Z; Zhang H; Wang L; Tian C; Yuan M; Yang X; Li X; Shang H; Xiong X; Xing Y
Front Immunol; 2019; 10():1592. PubMed ID: 31354731
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 inflammasome pathways in atherosclerosis.
Baldrighi M; Mallat Z; Li X
Atherosclerosis; 2017 Dec; 267():127-138. PubMed ID: 29126031
[TBL] [Abstract][Full Text] [Related]
18. Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis.
Li X; Zhang Y; Xia M; Gulbins E; Boini KM; Li PL
PLoS One; 2014; 9(1):e87552. PubMed ID: 24475307
[TBL] [Abstract][Full Text] [Related]
19. Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport.
Luo J; Wang X; Jiang X; Liu C; Li Y; Han X; Zuo X; Li Y; Li N; Xu Y; Si S
FASEB J; 2020 Jan; 34(1):1398-1411. PubMed ID: 31914630
[TBL] [Abstract][Full Text] [Related]
20. Nur77 Deficiency Exacerbates Macrophage NLRP3 Inflammasome-Mediated Inflammation and Accelerates Atherosclerosis.
Yuan R; Zhang W; Nie P; Lan K; Yang X; Yin A; Xiao Q; Shen Y; Xu K; Wang X; Pan X; Shen L; He B
Oxid Med Cell Longev; 2022; 2022():2017815. PubMed ID: 35464766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
